14.02
0.02 (0.18%)
| Previous Close | 13.99 |
| Open | 14.02 |
| Volume | 128,941 |
| Avg. Volume (3M) | 320,009 |
| Market Cap | 869,342,016 |
| Price / Book | 3.01 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -0.790 |
| Total Debt/Equity (MRQ) | 0.21% |
| Current Ratio (MRQ) | 29.71 |
| Operating Cash Flow (TTM) | -41.26 M |
| Levered Free Cash Flow (TTM) | -27.93 M |
| Return on Assets (TTM) | -11.97% |
| Return on Equity (TTM) | -16.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | GH Research PLC | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.88% |
| % Held by Institutions | 68.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Highvista Strategies Llc | 30 Sep 2025 | 241,894 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (HC Wainwright & Co., 149.73%) | Buy |
| Median | 27.00 (92.65%) | |
| Low | 19.00 (Needham, 35.57%) | Buy |
| Average | 27.00 (92.65%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 13.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Nov 2025 | 35.00 (149.73%) | Buy | 13.54 |
| Needham | 13 Oct 2025 | 19.00 (35.57%) | Buy | 12.96 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2025 | Announcement | GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates |
| 09 Oct 2025 | Announcement | GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |